Mako: NSU Undergraduate Student Journal
Volume 2020 Spring

Article 4

February 2020

The Interplay of the Oral-Gut Microbiome with Chronic
Inflammation in Rheumatoid Arthritis and Crohn's Disease
Anuradha Rampersaud
Nova Southeastern University, ar2171@mynsu.nova.edu

Follow this and additional works at: https://nsuworks.nova.edu/mako
Part of the Immune System Diseases Commons, Medical Immunology Commons, Medical
Microbiology Commons, and the Nutritional and Metabolic Diseases Commons

This Research Article has supplementary content. View the full record on NSUWorks here:
https://nsuworks.nova.edu/mako/vol2020/iss1/4
Recommended Citation
Rampersaud, Anuradha (2020) "The Interplay of the Oral-Gut Microbiome with Chronic Inflammation in
Rheumatoid Arthritis and Crohn's Disease," Mako: NSU Undergraduate Student Journal: Vol. 2020 , Article
4.
Available at: https://nsuworks.nova.edu/mako/vol2020/iss1/4

This Research Article is brought to you for free and open access by NSUWorks. It has been accepted for inclusion
in Mako: NSU Undergraduate Student Journal by an authorized editor of NSUWorks. For more information, please
contact nsuworks@nova.edu.

The Interplay of the Oral-Gut Microbiome with Chronic Inflammation in
Rheumatoid Arthritis and Crohn's Disease
Cover Page Footnote
1. Author: Anuradha Rampersaud, B.S; Nova Southeastern University, College of Healthcare Sciences 2.
Mentor: Dr. Julie Torruellas Garcia, Ph. D; Nova Southeastern University, HALMOS College of Natural
Sciences and Oceanography

This research article is available in Mako: NSU Undergraduate Student Journal: https://nsuworks.nova.edu/mako/
vol2020/iss1/4

Rampersaud: The Interplay of the Oral-Gut Microbiome with Chronic Inflammatio

Rampersaud, Anuradha

The Interplay of the Oral-Gut Microbiome with Chronic Inflammation in Rheumatoid Arthritis
and Crohn's Disease
Anuradha Rampersaud1 and Julie Torruellas Garcia2
1

College of Healthcare Sciences, Nova Southeastern University, 3301 College Ave., Fort

Lauderdale, FL 33314
2

Department of Biological Sciences, Halmos College of Natural Sciences and Nova Southeastern

University, 3301 College Ave., Fort Lauderdale, FL 33314

Corresponding Author: Anuradha Rampersaud – Email: ar2171@mynsu.nova.edu

Published by NSUWorks,

1

Mako: NSU Undergraduate Student Journal, Vol. 2020 [], Art. 4

INTERPLAY OF RA AND CD

1

Abstract
Rheumatoid Arthritis (RA) and Crohn’s Disease (CD) are both chronic inflammatory diseases
that share developmental and treatment similarities. RA’s symptoms include swelling, stiffness,
and pain in synovial joints, corresponding with bone and cartilage destruction. CD’s symptoms
include abdominal pain, bowel obstruction, bloating, diarrhea, and fever. The purpose of this
literature review was to investigate the links between these two diseases and propose future
treatment and prevention targets. Current treatment for RA and CD aims to suppress
inflammation by targeting its mediators. However, this review noted that there should be greater
focus on resolving inflammation. Both diseases are characterized by the non-resolution of
chronic inflammation due to the interplay of specific cytokines (IL-1, IL-6, TNF), which are
proteins that function in cell to cell communication, and due to the dysbiosis of the oral and gut
microbiome, which involves a compositional change of residing bacteria. Individuals are
predisposed to both diseases via heritability and environmental factors, such as smoking. Finally,
development and severity of both diseases depend on mutations in specific regulatory genes,
such as STAT4 and PTPN2/22. Targeting the influx of immune cells, stimulating pro-resolving
mediators such as IL-9 and 10, and restoring eubiosis are possible inflammation-resolving
mechanisms. There should also be a movement towards prevention rather than disease
intervention. Prevention tactics may include the promotion of oral and gut health, quitting
smoking, and screening for genetic susceptibility.
Keywords: Rheumatoid Arthritis, Crohn’s Disease, dysbiosis, inflammation
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The Interplay of the Oral-Gut Microbiome with Chronic Inflammation in Rheumatoid Arthritis
and Crohn’s Disease
Introduction
A malfunctioning immune system is the cornerstone of autoimmune diseases, cancers,
and chronic inflammatory diseases. The immune system is composed of leukocytes, cytokines,
chemokines, antimicrobial proteins, and barriers, to help to protect the body against foreign
invaders. When it malfunctions, local tissue damage and widespread inflammation can result.
Rheumatoid Arthritis (RA) and Crohn’s Disease (CD) are chronic inflammatory conditions that
result from inappropriate immune responses against self-antigens and commensal bacteria,
respectively.
RA has become an increasingly prominent extraintestinal manifestation of CD (Yang et
al., 2018; Georgiadis, Tzambouras, Ioachim, Tsianos, Agnantis, & Drosos, 2003). For example, a
study in South Korea found that RA was found in 10/1000 CD cases (Yang et al., 2018). This
association begs the following question: Are RA and CD merely coexisting diseases for some
patients or do they share genetic and environmental links that point to similar developments?
This literature review aims to investigate the treatments, inflammatory, environmental, and
genetic susceptibility factors shared by RA and CD. This analysis will then be used to propose
possible treatment and diagnosis options that could target both diseases to prevent or delay
disease onset.
Role of Chronic Inflammation in RA and CD Etiology
RA Overview
RA is a T cell mediated autoimmune disorder that affects approximately 1% of the
world’s population (Cusick, Libbey, & Fujinami, 2012). RA is characterized by inflammation of
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the synovial membrane surrounding the joints. RA’s synovial inflammation leads to cartilage
damage, bone erosion, thickening of the synovial membrane, formation of rheumatoid nodules,
fatigue, stiffness and swelling of joints (Klareskog, Catrina & Paget, 2009; Chauhan & AlDhahir, 2018). The bone and cartilage damage present in RA patients are due to matrix
metalloproteinases (MMPs). MMPs, released by macrophages and fibroblasts, work to gradually
destroy the proteins needed to maintain the extracellular matrix structure. Extra-articular damage
is also present with RA comorbidities, such as cardiovascular disease, osteoporosis, and
lymphomas (Klareskog et al., 2009). A loss of tolerance towards citrullinated proteins is the
hallmark of RA autoimmunity. The enzyme, peptidylarginine deiminase (PAD), facilitates the
citrullination of proteins. Citrullinated proteins are presented by MHC Class II, where they are
eventually recognized by T cells. These T cells proceed to interact with and activate B cells,
which then produce and release antibodies against citrullinated protein antigens (ACPAs).
ACPAs can recognize, bind, and neutralize the citrullinated protein antigen. ACPA is used as a
diagnostic tool and a measure of RA severity, since its serum levels are correlated to the severity
of RA symptoms (Du Teil Espina, Gabarrini, Harmsen, Westra, Winkelhoff & Van Dijl, 2018).
CD Overview
CD is a type of Inflammatory Bowel Disease (IBD) that involves inflammation of the
gastrointestinal tract, particularly the distal ileum (Ranasinghe & Hsu, 2018). The chronic
inflammation associated with CD is responsible for the ulceration of the mucosal layers and
granuloma formation in the distal small intestine (Boyapati, Satsangi, & Ho, 2015). Chronic
inflammation develops due to the malfunctioning immune system incorrectly identifying normal
flora as pathogenic (Margo & Portela, 2010). One of the most widely studied genetic risk factor
for CD is the Nucleotide-binding oligomerization domain-containing protein 2 (NOD2),
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previously known as CARD15. NOD2 is expressed in immune cells and intestinal epithelial
cells, termed Paneth cells. These proteins are essential in turning on the Nuclear Factor-Kappa-B
(NF-kB) pathway. Mutations of the NOD2 gene are found in 40% of Western CD patients and
disrupt the protein’s ability to recognize foreign microbes (Boyapati et al., 2015). This then
negatively affects the cell’s ability to process intracellular microbes (Boyapati et al., 2015). This
malfunctioning immune response is further amplified by a leaky epithelial barrier, non-regulation
of T cells, increased persistence of Toll-like Receptors (TLRs), and impaired autophagy (Margo
& Portela, 2010; Baumgart & Sandborn, 2012). The impaired intestinal epithelial barrier is due
in part to the action of Paneth cells. Paneth cells participate in the immune response by releasing
antimicrobial granules. In CD, Paneth cells tend to have the 300T autophagy gene variant which
decreases and disrupts granule release and autophagy (Baumgart & Sandborn, 2012). The
epithelial layer is further compromised by the leaky tight junctions which allows for the invasion
of more immune cells. These defective immune responses irritate the intestinal lining and
mucosal layer and lead to symptoms, such as abdominal pain/tenderness, diarrhea, digestive tract
irritation, bloating, gas, fever, weight loss, and anemia (NIH, 2017; Ranasinghe & Hsu, 2018).
Non-resolution of Chronic Inflammation
RA and CD are chronic inflammatory diseases, mediated mainly by neutrophils,
macrophages, dendritic cells, and Helper T cells, Th1 and Th17. Inflammation is an immunesystem mediated process that is typically activated after tissue injury or invasion of a pathogen.
These stimuli then promote leukocytes, such as macrophages and mast cells, to release
proinflammatory proteins and chemicals, termed mediators. Chemical messengers, known as
cytokines, move from cell to cell and communicate with them to release more inflammatory
signals. The most prevalent proinflammatory cytokines in RA and CD are Interleukins (IL-1, IL-
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6, IL-12, IL-17), Interferon (IFN), and Tumor Necrosis Factor (TNF). TNF is one of the most
essential perpetrators in RA and CD progression. TNF is produced by mononuclear phagocytes
and induces angiogenesis and adhesion molecule expression (Ticani, Andreoli, Bazzani, Bosiso,
& Sozzani, 2007). Release of proinflammatory cytokines facilitates the dilation of blood vessels,
which allows more leukocytes, such as neutrophils and macrophages, to relocate to the infectedarea via chemotaxis. The extravasation of leukocytes is mediated by endothelial cells’ selectins
and integrins. Once these leukocytes reach the target area, they release more cytokines, granules,
enzymes, such as proteinase, and ROS/RNS that induce tissue damage (Medzhitov, 2008). The
entire inflammatory process causes redness, swelling, and heat release. Resolution of
inflammation occurs when the mediators are turned off or broken down by the body, in a cleanup
process. This cleanup process involves the cessation of white blood cell recruitment and the
removal of white blood cells from the infected area. Macrophages, especially the M2-Like ones,
participate in the clean up by removing dead leukocytes and releasing pro-resolving mediators.
Pro-resolving mediators include resolvin E1, Lipoxin A4, TGF-β, IL-9, adenosine, and proapoptotic factors (TRAIL, FasL) (Schett & Neurath, 2018). Resolution of inflammation protects
against further tissue damage. RA and CD are both characterized by the non-resolution of
inflammation. When inflammation is not shut off, leukocytes continue to release
proinflammatory meditators that lead to chronic tissue damage, granuloma formation, and
increasing severity of disease symptoms.
Environmental Factors Linked to RA and CD Susceptibility
Smoking
RA and CD share similar genetic and environmental susceptibility factors. Identifying
these susceptibility factors could help to shift how researchers and doctors tackle these immune-
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mediated diseases. More importantly, greater insight into the factors that increase one’s
susceptibility to these diseases could initiate a disease prevention initiative. One of the most
well-studied environmental risk factors for RA and CD is smoking. Studies with monozygotic
twins, in which one smoked and the other did not, demonstrated that the smokers developed RA
in 12/13 cases (Klareskog et al., 2009). Smoking acts as a risk factor for the rheumatoid factorpositive and ACPA-positive RA subsets (Klareskog et al., 2009). The reason for this lies in the
role of the PAD enzyme in exacerbating the autoimmune reactions in RA. When cigarette
particles enter the lungs, resident macrophages are activated and induce the death of lung cells.
This promotes the activity of the PAD enzyme. The resulting citrullinated proteins then bind to
MHC on immune cells and promote the synthesis of ACPAs (Klareskog et al., 2009). These
antibodies attack the body’s own cells, promote inflammation, and increase the severity of RA.
Similarly, smoking increases the risk of developing CD. This association has been linked
to a prevalent genetic susceptibility factor in CD. A prominent mutation in Paneth cells
(ATG16L1T300A) is triggered by tobacco smoke (Liu et al., 2018). This mutation leads to
Paneth cell dysfunction, which is characteristic of CD. This defect impairs autophagy and the
antimicrobial granule production (Baumgart & Sandborn, 2012). Furthermore, prenatal and
childhood exposure to second-hand smoking increases one’s chances of developing CD (Dutta &
Chacko, 2016). These findings illustrate that both RA and CD share smoking as an
environmental risk that could be controlled or ceased to prevent or delay the onset of these two
diseases.
Oral-Gut Dysbiosis
Another environmental risk factor shared by RA and CD is the irregularity of the oral-gut
microbiome. The oral-gut microbiome, a community of bacteria that reside in the gastrointestinal
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tract, mouth, skin, and urinary tract, has been shown to play an increasingly prominent role in the
development of CD and RA. Its association to CD is not as surprising considering that CD’s
etiology is in the intestinal tract; it is much more interesting to note the recent associations
between RA and the gut microbiome. Dysbiotic links shared between the two diseases highlight
more inflammatory causes that could be intervened as possible treatments.
The gut microbiome-inflammation link has both environmental and genetic components.
The gut microbiome irregularity, termed dysbiosis, is present in CD and RA patients. Dysbiosis
can be caused by various factors, such as diet, drug use, antibiotic use, and aging (Du Teil Espina
et al., 2018). However, recent research recognizes that dysbiosis may be a symptom and cause of
RA and CD. Dysbiosis involves an overall decrease in the diversity of gut bacteria (Hedin, Van
der Gast, Stagg, Lindsay, & Whelan, 2017), a decrease in Firmicutes (i.e. Clostridium,
Faecalibacterium prausnitzii), and an increase in the Proteobacteria phylum (i.e. Family:
Enterobacteriaceae such as Escherichia coli) (Boyapati et al., 2015; NIH, 2017; Hedin et al.,
2017). Interestingly, this decrease in bacterial diversity has also been linked to smoking,
colorectal cancer, and obesity (Hedin et al., 2017). Bacteria such as E. coli have been shown to
activate inflammation after interaction with epithelial cells. E. coli then induce macrophages to
release more proinflammatory chemical messengers, such as TNF (Boyapati et al., 2015). These
findings were further solidified after a University of Pennsylvania study concluded that the
Proteobacteria phylum also initiated intestinal inflammation in mice (Ni et al., 2017). This means
that Proteobacteria, which are already in high levels in the intestine of CD patients, induce
intestinal inflammation and continue to promote it. Another study analyzed the gut microbiota of
CD-afflicted and non-afflicted siblings. This study found that both siblings had similar gut
microbiota compositions and both displayed dysbiotic characteristics (Hedin et al., 2017).
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Therefore, dysbiosis is not merely a consequence of inflammatory conditions; it is also an
instigator in CD pathogenesis and a risk factor. It’s role as a susceptibility factor in CD
development could be a possible target for CD onset prevention.
Dr. Gary D. Wu and his team at the University of Pennsylvania investigated the role of
nitrogen metabolism in dysbiosis. The researchers found that there was an increase in nitrogen
metabolism and an increase in amino acid levels in the stools of CD patients; increased nitrogen
metabolism is due to certain bacteria producing the urease enzyme, which makes ammonia to
sustain growth (Ni et al., 2017; NIH, 2017). A positive correlation was found between urease
presence and dysbiotic activity. If there is more urease, then more amino acid/amino acid
derivatives will be produced. The study found that higher amino acid levels in fecal samples
correlated to more intestinal inflammation and higher levels of Proteobacteria. Interestingly,
when the researchers used a urease-negative E. coli strain, no signs of dysbiosis were present (Ni
et al., 2017). The negative results observed here indicates that dysbiosis development may
depend on the presence of bacterial urease. Such findings need to be observed in humans in order
to determine the role urease may play in causing gut dysbiosis, and therefore CD- intestinal
inflammation.
The health of the oral-gut microbiome in RA patients provides clues into the
development of RA. Oral dysbiosis in RA patients may include increases in bacteria such as
Lactobacillus salivarus, Prevotella, and Cryptobacterium curtum. Periodontitis, chronic
inflammation of the tissue surrounding teeth, has been linked to RA since 1918 (Du Teil Espina
et al., 2018). Patients with periodontitis are twice as likely to develop RA. The reason for this
lies in a bacterium that causes periodontitis, Porphyromonas gingivalis. P. gingivalis can travel
from the oral cavity, through the bloodstream, and into the synovial fluid surrounding the joints.
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P. gingivalis has an enzyme known as PPAD, that is similar in function to the PAD enzyme that
is essential in the development of RA auto-antibodies (ACPAs). This example of molecular
mimicry allows for a human’s antibodies to recognize the bacterial citrullinated proteins, thereby
inducing an immune response like that of RA ((Du Teil Espina et al., 2018). This response
aggravated the symptoms of RA (i.e. increased joint damage) by allowing the mobilization of
more immune cells, such as Th17, and increasing the production of proinflammatory cytokines
(IL-17) and autoantibodies (Du Teil Espina et al., 2018). P. gingivalis may further exacerbate the
inflammatory symptoms of RA by targeting neutrophils. Neutrophils in RA synovium exhibit
amplified Neutrophil Extracellular Traps (NETs) release, which is accompanied by the release of
citrullinated proteins, the same proteins that are recognized and targeted for destruction by the
ACPA antibodies. This continues the inflammatory and tissue-destructive cycle present in RA.
These results demonstrate that oral bacteria exert influence beyond the oral cavity. In the case of
RA, oral bacteria may contribute to gut dysbiosis. Oral bacteria’s ability to travel to and live in
the gut, alter the microbiome, and induce chronic inflammation needs to be curbed for patients
with dysbiosis and RA.
Genetic Factors Linked to RA and CD Susceptibility
RA and CD share genetic factors that play a role in the development and pathogenesis of
both diseases. RA’s heritability is about 60%, whereas CD’s heritability ranges from 25-42%
(Kurkó, Besenyei, Laki, Glant, Mikecz, & Szekanecz, 2013; Gordon, Trier, Moller, Andersen &
Harbord, 2015). Genetic factors contribute to approximately 50% of the overall development of
RA (Klareskog et al., 2009). There are approximately 30 loci implicated in RA’s development
(Kurko et al., 2013). Likewise, CD’s etiology is based on genetic mutations in over 71 loci on 17
chromosomes (Baumgart & Sandborn, 2012). CD’s genetic risk is further heightened by the fact
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that monozygotic twins have an increased risk of developing CD compared to dizygotic twins
(Baumgart & Sandborn, 2012). These results demonstrate that environmental and epigenetic
factors are not solely responsible for RA and CD development. One of the most well-studied
genetic factors for RA is HLA-DRB1, whereas NOD2/CARD15 is the most recognizable genetic
factor for CD. However, there are two major genetic mutations shared by both RA and CD that
occur in the PTPN2/22 and STAT4 genes. Understanding the underlying genetic causes of these
two diseases is essential in taking steps toward early diagnoses.
PTPN2/N22
One well researched correlation between the two is the mutations in certain immune
system regulatory genes, known as Protein Tyrosine Phosphatase Non-receptor type 2 and 22
(PTPN2/22) genes. These genes function to regulate immune responses by coding for
phosphatases. These phosphatases remove phosphate, from T cell receptors (TCR), Signal
Transducers and Activators of Transcription (STAT) dimers, and BH3-only proteins (BIM)
(Sharp, Beg, & Naser, 2018). BIM is a pro-apoptotic protein that is involved in the intrinsic
programmed cell death pathway (Gogada et al., 2012). The intrinsic apoptosis pathway is in the
mitochondria of cells and allows for the release of caspase proteins. The STAT1 gene codes for a
STAT protein that plays a role in JAK/STAT cytokine receptor signaling (NCBI, 2019). In this
pathway, a cytokine binds to receptors on the surface of a target cell. These receptors dimerize
and bring two Janus Kinase (JAK) molecules together for activation. The tails of the receptors
act as binding sites for STATs. Once JAK phosphorylates STAT, STAT dimerizes and changes
shape in order to enter the nucleus of the cell. Once there, various STATs will promote cell
proliferation, differentiation, and growth. The TCR binds to presented antigens and is then
activated to stimulate various signal transduction pathways. Activation of T cells have vastly
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different effects depending on the type of T cell. The lack of phosphates on the TCR and BIM,
inactivate them (Sharp et al., 2018). Dephosphorylation of STAT prevents it from dimerizing
and entering the nucleus. As such, this negatively regulates chemokine production (Sharp et al.,
2018). Mutations of the PTPN2/22 genes could interfere with the regulation of the immune
response. Without proper dephosphorylation, TCRs, BIMs, and STATs will be unrestrictedly
active. In RA and CD, this would stimulate T cells to constantly secrete proinflammatory
cytokines and hinder the ability of epithelial cells in the joints and intestine to induce leukocyte
cell death. This would lead to a toxic cycle of activated leukocytes promoting inflammation.
A study performed by Dr. Saleh Naser and his team at the University of Central Florida
sought to determine which mutations on the PTPN2/22 genes were responsible for the
hyperproliferation of T cells in RA. The study found that the single nucleotide polymorphism
(SNP) rs478582 in PTPN2 and rs2476601 in PTN22 were significant in the development of RA.
Dr. Naser and his team concluded that patients with both mutations had 6.5-fold more risk of
getting RA than the control subjects. The PTPN22 rs2476601 SNP (location: 1p12) was also
identified as a susceptibility locus for CD. Different SNPs in PTPN2 such as rs1893217,
rs740495, and rs1736020, were identified in CD (Baumgart & Sandborn, 2012). The rs2476601
and rs478582 SNPs increased T cell proliferation and the expression of Interferon-y (IFN-y).
Greater T cell proliferation as mentioned earlier means that there was a lack of regulation by
PTPN2/N22. This would further promote the inflammatory cycle seen in RA. Interestingly, not
only were the mutations that inhibited PTPN2/22 prevalent in RA subjects, but overall there was
less PTPN2/22 mRNA expression (Sharp et al., 2018). This indicates that mutations and overall
reduced expression of these two regulatory genes exacerbate the disease process. It does so by
allowing the TCR to be responsive to antigen presentation by an antigen-presenting cell that was
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stimulated by proinflammatory cytokines, such as TNFα and IL-1. Activation of the TCR then
initiates the NF-kB signaling pathway. This pathway ends when the NF-kB transcription factor
goes to the nucleus and stimulates the expression of cytokines and chemokines. These cytokines
bind to epithelial cells, stimulate the JAK/STAT pathway to produce more chemokines, and
inhibit apoptosis. Both RA and CD feature an imbalance between T effector cells and regulatory
T cells (Treg). As such, Th cells, particularly Th17, are overactive, whereas Treg cells are not.
When Th17 cells are continually activated and present in large amount, they induce greater tissue
damage by producing more IL-17 and 1L-22. Since both RA and CD are heavily T cell mediated,
the consequences of PTPN2/22 dysfunction and its role in the T effector and Treg cell imbalance
need to be further investigated.
STAT4
Another genetic susceptibility factor shared by RA and CD is STAT4. As mentioned
above, STAT encompasses a group of transcription factor proteins that play a role in signal
transduction pathways. STAT4 is located within dendritic cells and macrophages (Gu et al.,
2015). STAT4 is responsible for promoting the differentiation of T cells into helper T cells,
particularly Th1 and Th17, the activation of monocytes, and the production of IFN-y, IL-12, and
IL-23 (Glas et al., 2010). This transcription factor plays a role in the pathogenesis of both RA
and CD. In CD, STAT4 has been shown to be constitutively activated. One genotypic study
performed by Dr. Stephan Brand and his team from the University of Munich, found that the
patients homozygous for STAT4 SNP rs7574865 presented with earlier onset of CD symptoms
and more frequent disease compared to the wildtype and heterozygous genotypes (Glas et al.,
2010). The association between RA and STAT4 has been studied for well over a decade.
However, there are some discrepancies in the overall conclusions of these case-control studies;
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the main discrepancy lies between ethnic groups. Some studies have found no significant
correlation between STAT4 mutations and RA, whereas others have when using a different
ethnic group as the test and control subjects. For example, one case study found that the minor T
allele of the STAT4 SNP rs7574865 was not significantly associated with Syrian RA patients
(Tarakji, Habbal, & Monem, 2018). On the other hand, a meta-analysis conducted by a team of
researchers in China, demonstrated that ethnicity and genotype play a role in the degree of
susceptibility conferred by the STAT4 SNP rs7574865 gene. According to this analysis, the TT,
GT +TT, and T allele genotypes were significantly associated with RA within the European,
Asian, African, and Latin American ethnic groups (Gu et al., 2015). These associations were
independent of whether the subject had Rheumatoid Factor-positive or negative RA. While there
is still not a conclusive theory of the association between RA and the STAT4 SNP, the status of
STAT4 in RA-affected joints is conclusive; STAT4 over-expression in the synovium of RA
patients is linked to the rs7574865 mutation (Gu et al., 2015). Nonetheless, this degree of
uncertainty concerning STAT4 and RA’s association highlights a major issue when testing for
susceptibility genes: patients diagnosed with the same disease may have varying genetic causes.
Ethnicity may be an important environmental factor that could hint at varying degrees of
susceptibility to diseases. Therefore, it is imperative that the healthcare paradigm move towards
individual screenings, and treatments for people who present similar symptoms of a disease.
Current Treatments for RA and CD
RA and CD share more than the same susceptibility factors; they share much of the same
treatments. There are no cures for RA and CD; as such, treatment is geared towards reducing or
resolving symptoms. The current treatments for RA and CD range from synthetic drugs to
biologic agents; nonetheless the focus of treatment is mainly on suppressing inflammation,
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reducing disease activity and potentially entering a remission state. This stems from the treat-totarget approach utilized in autoimmune disease intervention.
The main classes of drugs prescribed are disease-modifying antirheumatic/antiinflammatory drugs (DMARDs/DMAIDs), glucocorticoids, and nonsteroidal anti-inflammatory
drugs (NSAIDs). The main issues with common RA and CD drugs are the risk of aggravating
comorbidities, high costs, and side effects. NSAIDs such as aspirin and acetaminophen, reduce
swelling but are not as commonly prescribed when treating CD because of their tendency to
irritate the intestinal lining (Crohn’s and Colitis Foundation, 2005). NSAID side effects also
include osteoporosis, hypertension, and ulceration in RA patients (Sharp et al., 2018).
Glucocorticoids, such as Prednisone, mimic the effects of cortisol and suppress the immune
system. However, they are not for long-term use because of the higher risk of infections and
cardiovascular complications compared to other treatment types (Burmester & Pope, 2017).
DMARDs and DMAIDs are used to intervene the damage to the joints and intestinal mucosa.
The common DMARDs are listed in Table 1 below. The most commonly prescribed synthetic
DMARD is Methotrexate. Methotrexate is often used as the initial monotherapeutic drug when
starting RA treatment. Conventional DMARDS, such as Methotrexate, can lead to fatigue, liver
damage, nausea, cytopenia, intolerance by the gastrointestinal tract, and increased risk of
infections (Burmester & Pope, 2017). Furthermore, Methotrexate is not advised for women who
intend to bear children and for those with liver conditions (Baumgart & Sandborn, 2012).
However, combination therapy of Methotrexate with a biologic agent can be more effective than
monotherapy (Burmester & Pope, 2017).
Biologic agents are more targeted; however, they do increase the risk of acquiring
infections, higher cholesterol, psoriasis and congestive heart failure (Burmester & Pope, 2017).
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Biologics are typically delivered via injections. Specific biologic drugs target different chemicals
and proteins in the body, and thereby lead to unique adverse events. For example, drugs that
inhibit JAK, such as Tofacitinib, could promote gastrointestinal side effects and lymphopenia.
The most commonly used biologic in RA and CD treatment is anti-TNF (Sharp et al., 2018). The
side effects of anti-TNF drugs include increased risk of tuberculosis, herpes zoster infection,
psoriasis, hepatotoxicity, and lymphomas (Burmester & Pope, 2017; Park & Jeen, 2018).
Another complication with the use of biologic therapies is the threat of anti-drug antibody
formation. The body may recognize a drug-based monoclonal antibody as a foreign threat and
seek to eliminate it. The drug would be treated as a foreign antigen and be presented to T and B
cells. This would then lead to the differentiation of plasma cells which will secrete antibodies
against the drug. These antibodies neutralize or lower the half-life of the drug (Fiehn, 2016).
This was seen in popular anti-TNF biologics, such as Infliximab and Adalimumab (Fiehn, 2016).
Methotrexate used in conjunction with a biologic agent, has been shown to decrease the
production of anti-drug antibodies and thereby increase the survival of the drug in the body. This
demonstrated that combination therapy with methotrexate and a biologic is more effective. This
treatment approach helps to lower inflammation, while also reducing tissue damage (Klareskog
et al., 2009). Another significant benefit of anti-TNF and methotrexate combination therapy is
the decreased threat to the cardiovascular system (Fiehn, 2016). Combination therapy, while the
most efficient, is still only effective in half of CD treatment cases (Boyapati et al., 2015). The
complications associated with synthetic drugs and biologic agents often lead to patients
constantly changing drugs or changing doses. Ten years after diagnosis with CD, approximately
47% of patients need surgery, but still relapse afterwards (Bressler et al., 2015). With RA drug
therapy, 40% of patients still become disabled in ten years (Chauhan & Al-Dhajir, 2018). More
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effective treatment options need to be developed in order to resolve chronic inflammation and
achieve long-lasting remission.
Table 1. Common DMARDs Used to Treat RA and CD
Drug

Formula

Purpose

Methotrexate

Folate antagonist

Inhibits adenosine
metabolism

Infliximab

IgG monoclonal antibody

Anti-TNF

Etanercept

TNF receptor with IgG1’s FC
domain

Anti-TNF

Adalimumab

Human IgG monoclonal
antibody

Anti-TNF

Anakinra

IL-1 receptor antagonist

Binds to IL-1 receptor to
prevent IL-1 from binding
to its receptor

Tofacitinib (Xeljanz)&
Baricitinib

Janus Kinase Inhibitor

Binds to JAK and stops
activation of the
JAK/STAT pathway

Tocilizumab

Monoclonal antibody

Anti-IL6 receptor

Rituximab

Monoclonal antibody

Anti-CD20-deactivates B
cells

Abatacept

CTLA4 and Fc region of IgG

Blocks the CD28-B7
interaction by binding to
B7 ligand on APCs

RA and CD Disease Prevention and Intervention Proposals
The previous discussion about the most common treatments for RA and CD has made it
clear that new treatment avenues need to be taken. Treating just the symptoms of RA and CD is
not enough. Remission for both diseases could be achieved if the diseases are treated early in
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order to stop major tissue damage (Hanauer, 2017). Therefore, better preventive steps should be
implemented. Since RA and CD have relatively high heritability and genetic causal factors, predisease genetic screening is essential in identifying one’s degree of susceptibility to these
diseases. Since RA typically affects older adults, with typical disease onset during the range of
30 to 60 years old, genetic screenings should be conducted at the age of 30 and every ten years
afterwards. CD’s onset targets a younger population ranging from 15 to 35 years old. As such,
genetic screenings should take place after puberty onset and every ten years afterwards.
Identification of the PTPN2/22 and STAT4 mutations early could allow for proper steps to be
taken to delay onset of the two diseases. Additionally, the oral and gut microbiota of patients
with moderate to severe RA and CD should be analyzed. Proper analysis could identify dysbiosis
as a factor in disease progression. Therefore, appropriate steps, such as the use of probiotics, can
be taken to correct this measure. Furthermore, a disease prevention initiative could be undertaken
in primary care clinics to address the importance of oral health and cessation of smoking.
Patients need to be informed of the effects of P. gingivalis on oral health and inflammation, so
that they may take steps in their daily routines to help lower the severity of RA symptoms.
Furthermore, all individuals whom are genetically susceptible to RA and/or CD should be
informed of the risks smoking carries, in order to eventually develop a plan to limit or quit the
habit to lessen the risk of developing these diseases.
Treatments to Limit Leukocyte Extravasation
Currently, the most common biologic treatment for both RA and CD is anti-TNF drugs.
These drugs neutralize TNF cytokines, which does play an essential role in perpetuating chronic
inflammation. However, TNF is just a mediator of inflammation. As mentioned above, anti-drug
antibody formation and increased risks of infections are major risks associated with Anti-TNF
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treatment. Anti-TNF treatment can lead to primary non-response in 10-30% of patients, and loss
of response in 23-46% of patients (Park & Jeen, 2018). Nonetheless, immunotherapy can be a
highly selective and potent treatment when used properly. Cytokines do not remain in one
location; chemotaxis allows distant leukocytes to respond to the cytokine signals and translocate.
Leukocytes respond to these chemical signals and release more proinflammatory factors. As
such, greater emphasis needs to be on targeting leukocytes themselves. Limiting the
extravasation of neutrophils via use of anti-integrins may be the key. Integrins are heterodimeric
receptors on the surface of leukocytes, which interact with adhesion molecules on endothelial
cells. Targeting integrin would limit the influx of leukocytes into inflamed tissues. A possible
target for both diseases would be α4β1, an integrin molecule expressed on many leukocytes. One
anti-integrin drug, Natalizumab (anti-α4 subunit), became a premier treatment for CD. However,
the drug unintentionally reached the central nervous system and lead to increased risk of brain
infections. This dilemma mimics a common trend with current biologic agents: these agents tend
to have systemic effects, rather than local effects. Systemic immunosuppression leads to adverse
side effects and increased risks of infections. Therefore, more precisely targeted immunotherapy
options must be pursued. For CD, specifically, α4β7 would be apt target because it is found on
GI lymphocytes (Park & Jeen, 2018). As such, Vedolizymab, an IgG antibody against α4β7
integrin that is specific to the intestine, is a better option for CD patients. Clinical trials have
shown that Vedolizymab initiated mucosal healing, did not affect brain immunity, and only had a
4% chance of developing anti-drug antibodies (Park & Jeen, 2018). Its side effects include
headache, nausea and nasopharyngitis, which are must less severe than Anti-TNF inhibitor side
effects. A similar RA treatment targeting integrins specific to the synovial membrane, such as
α5β1 integrin which recognizes fibronectin, α1β1, α10β1, and α11β1 which recognize collagen,
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could be successful in limiting lymphocyte extravasation (Lowin & Straub, 2011). Intercepting
extravasation could be extremely beneficial to patients suffering from numerous inflammatory
conditions as it stops the cycle of cytokine-lead inflammation. Further research on the effects of
tissue-specific anti-integrin therapies need to be conducted to gauge the efficacy and safety of
such treatments.
Another treatment aimed at limiting extravasation is E6011. E6011 is currently
undergoing clinical trials for CD. E6011 is a monoclonal IgG antibody that targets fractalkine
(FKN), which is a CX3C chemokine that enables integrin-independent and dependent leukocyte
extravasation (Tanaka et al., 2017). E6011 has already shown promising results for RA patients;
E6011 reduces inflammation and leads to decreased swelling and tenderness around joints
(Tanaka et al., 2017). The adverse effects of E6011 are much less severe than other biologic
agents, thereby making it a promising immunotherapy.
The Use of IL-9 and ILC2 in Resolving Inflammation
RA and CD are characterized by the non- resolution of inflammation. Current biologic
treatments tend to target proinflammatory cytokines. However, there are pro-resolving cytokines
that could be the future of cytokine-targeted therapy. One promising avenue is the use of Type 2
Innate Lymphoid Cells (ILC2s). ILC2s produce IL-9, IL-4, and IL-13, activate Treg’s, and trigger
the expression of the M2 macrophage phenotype (Schett & Neurath, 2018). IL-9 and ILC2 levels
are lowered in patients with RA (Rauber et al., 2017). IL9 overexpression has been shown to
accelerate the resolution of RA, resolve joint swelling, reduce synovitis, and lower tissue damage
and bone erosions by activating ILC2s in mice models (Rauber et al., 2017). IL-9’s antiinflammatory effects could also be useful in reducing granuloma and mucosal damage in CD.
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Promoting ILC2 and IL-9 expression could possibly the key to resolving inflammation and
inducing tissue repair in chronic inflammatory conditions.
Restoring Eubiosis via Probiotics
This literature review delved into the association between dysbiosis and RA and CD.
Dysbiosis seems to be both a causal factor and an effect of the two diseases. As such, proper
preventative and interventionist measures could be taken to reduce the risk of getting these
diseases in genetically predisposed individuals or to decrease the chronic inflammation in
already affected patients. One possible treatment avenue is the use of probiotics to restore
eubiosis. Prevotella histicola, Lactobacillus casei, and Lactobacillus paracasei have been shown
to be possible routes to eubiosis. P. histicola ameliorates arthritis in mice; L. casei uses
lactoceptin, a protease, to reduce the amount of proinflammatory cytokines in RA patients (Du
Teil Espina et al., 2018). L. casei is already a marketable probiotic; it is found in certain
probiotic supplements, cheeses and yogurts. One study found that Lactobacillus rhamnosus
stopped the formation and release of NETs (Du Teil Espina et al., 2018). Limiting NETosis
would decrease the amount of ACPAs, as mentioned earlier in this paper. Another promising
probiotic is commensal bacteria, Faecalibacterium prausnitzii, which are decreased in dysbiotic
individuals. F. prausnitzii has been shown to be anti-inflammatory by decreasing the IL-8
levels, increase pro-resolving IL-10 levels (Martin et al., 2017). The brand, OMNI-Biotic created
a supplement which contains fructo-oligosaccharides and galacto-oligosaccharides to promote
the proliferation of F. prausnitzii. Therefore, the bacterial growth is being promoted indirectly.
In the future, more direct administration of the probiotic could be a more potent therapy. The use
of probiotic therapy may be the key to restoring eubiosis, which might then limit the symptoms
of chronic inflammation. Further testing needs to be conducted with human subjects in order to
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measure the effects of probiotic treatment on dysbiosis and inflammation. Dysbiosis may also be
countered by more invasive measures, such as a fecal microbial transplantation (FMT). Targeting
P. gingivitis is another probable method. P. gingivitis exacerbates inflammation due to molecular
mimicry. One study showed that an antibody against the fibrillin protein made by P. gingivitis
helps to alleviate periodontitis and RA. For patients with extreme dysbiosis, the use of antibiotics
may be helpful. The study conducted by Dr, Wu and his team at the University of Pennsylvania
demonstrated that a combination therapy of vancomycin, neomycin, and PEG altered the
microbiota of subjects favorably (Ni et al., 2018). However, the use of antibiotics must be
cautioned due to their ability to further decrease the diversity of the gut microbiota. Therefore,
probiotics could be the least aggressive option in restoring eubiosis.
Concluding Remarks
RA and CD share genetic and environmental factors that lead to disease onset and
progression. The current treatments for RA and CD are aimed towards inflammation suppression
and have adverse side effects that limit long term use of the same medication and dosage.
Therefore, the use of anti-integrins and pro-resolving cytokines could help to resolve
inflammation, while the use of probiotics could naturally restore gut eubiosis. Overall, health
promotion and disease prevention initiatives targeted towards smoking and oral/gut health could
be of great value in delaying the onset of these diseases in genetically predisposed individuals.
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Appendix A

Table 2. Abbreviations
Abbreviation

Definition

ACPA

Antibodies against citrullinated protein antigens

BIM

BH3-only protein

CD

Crohn’s Disease

DMAID

Disease modifying anti-inflammatory drug

DMARD

Disease modifying anti-rheumatic drug

FasL

Fas Ligand

HLA-DRB1

Human leukocyte antigen DRB1gene

IFN

Interferon

Ig

Immunoglobulin (antibody)

IL

Interleukin

ILC2

Type 2 innate lymphoid cell

JAK

Janus kinase

MHC

Major histocompatibility complex

MMP

Matrix metalloproteinase

NET

Neutrophil extracellular trap

NF-κB

Nuclear factor kappa light chain enhancer of
activated B cells

NOD

Nucleotide binding oligomerization domain
containing protein

NSAID
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PAD

Peptidylarginine deiminase

PTPN2/22

Protein tyrosine phosphatase non-receptor type 2
and 22

RA

Rheumatoid Arthritis

ROS/RNS

Reactive oxygen/nitrogen species

SNP

Single nucleotide polymorphism

STAT

Signal transducer and activator of transcription

TCR

T cell receptor

Th

Helper T cell

TLR

Toll like receptors

TNF

Tumor necrosis factor

TRAIL

TNF-Related Apoptosis Inducing Ligand

Treg

Regulatory T cell
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